For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241203:nRSC6706Oa&default-theme=true
RNS Number : 6706O Tate & Lyle PLC 03 December 2024
Transactions in Own Securities
3 December 2024
Tate & Lyle plc (the "Company") announces that it has purchased the
following number of its ordinary shares from Merrill Lynch International
("BofA") as part of its share buyback programme announced on 20 June 2024 (the
"Programme").
Date of purchase: 3 December 2024
Number of ordinary shares of £0.2916666667 each purchased: 211,256
Highest price paid per share (£): 7.32
Lowest price paid per share (£) : 7.25
Volume weighted average price paid per share (£): 7.26
The repurchased shares will be held in treasury. Following the purchase of
these shares, the Company holds 27,404,461 of its ordinary shares in treasury
and has 449,319,760 ordinary shares in issue (excluding treasury shares).
Aggregated Information
Date Trading venue Volume weighted average price (£ per share) Number of Shares Purchased
3 December 2024 London Stock Exchange 7.25 182,200
3 December 2024 Chi-X (CXE) 7.28 23,753
3 December 2024 BATS (BXE) 7.27 5,303
Transaction Details
In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No
596/2014 as it forms part of UK law, a full breakdown of the individual trades
made by BofA on behalf of the Company as part of the Programme is detailed on
the attached:
http://www.rns-pdf.londonstockexchange.com/rns/6706O_1-2024-12-3.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/6706O_1-2024-12-3.pdf)
The LEI reference for Tate & Lyle PLC is 2138008K14474WPKZ244.
For further information please contact:
Christopher Marsh, VP, Investor Relations
Mobile: +44 (0)7796 192 688
Nick Hasell (FTI Consulting), Media Relations
Mobile: +44 (0)7825 523 383
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSTJBRTMTBMBLI